Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

HALO

Halozyme Therapeutics Inc

Apr 27 • 04:00PM ET

64.49

-0.87 -1.33 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: VRTX BIIB REGN AMGN GILD NBIX INCY ALNY EXEL IONS

| Held by: IJH VTI VB VBK XBI VXF FBT MDY IBB XMHQ

Scroll to Statements

Index	-	P/E	25.88	EPS (ttm)	2.49	Insider Own	1.06%	Shs Outstand	117.78M	Perf Week	-7.30%
Market Cap	7.64B	Forward P/E	6.51	EPS next Y	9.91	Insider Trans	-17.40%	Shs Float	117.22M	Perf Month	1.90%
Enterprise Value	9.67B	PEG	0.17	EPS next Q	1.54	Inst Own	104.75%	Short Float	12.16%	Perf Quarter	-7.70%
Income	316.89M	P/S	5.47	EPS this Y	94.22%	Inst Trans	2.63%	Short Ratio	8.07	Perf Half Y	-3.58%
Sales	1.40B	P/B	155.61	EPS next Y	22.95%	ROA	12.99%	Short Interest	14.26M	Perf YTD	-4.18%
Book/sh	0.41	P/C	53.50	EPS next 5Y	38.33%	ROE	153.59%	52W High	82.22 -21.56%	Perf Year	6.61%
Cash/sh	1.21	P/FCF	11.85	EPS past 3/5Y	21.17% 22.89%	ROIC	14.31%	52W Low	47.50 35.77%	Perf 3Y	100.03%
Dividend Est.	-	EV/EBITDA	10.70	Sales past 3/5Y	28.38% 39.16%	Gross Margin	78.13%	Volatility	3.32% 2.90%	Perf 5Y	26.18%
Dividend TTM	-	EV/Sales	6.93	EPS Y/Y TTM	-25.45%	Oper. Margin	58.45%	ATR (14)	2.03	Perf 10Y	488.95%
Dividend Ex-Date	-	Quick Ratio	3.66	Sales Y/Y TTM	37.55%	Profit Margin	22.69%	RSI (14)	42.51	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.66	EPS Q/Q	-213.27%	SMA20	-2.64%	Beta	0.90	Target Price	85.22
Payout	0.00%	Debt/Eq	44.61	Sales Q/Q	51.60%	SMA50	-3.96%	Rel Volume	0.75	Prev Close	65.36
Employees	423	LT Debt/Eq	44.37	Earnings	Feb 17 AMC	SMA200	-5.64%	Avg Volume	1.77M	Price	64.49
IPO	Mar 12, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-110.92% 3.69%	Trades		Volume	1,321,860	Change	-1.33%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Downgrade	Goldman	Neutral → Sell	$56
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform	$70
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$75
Jul-10-25	Resumed	Goldman	Neutral	$55
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$62
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform	$47
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Apr-08-26 05:32AM	Halozyme and Vertex sign deal for Hypercon technology (Hospital Management)
Apr-07-26 08:00AM	Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon Technology (PR Newswire)
Mar-12-26 08:30AM	Halozyme Appoints David Ramsay as Interim Chief Financial Officer (PR Newswire)
Mar-06-26 08:00AM	U.S. FDA Approves TECVAYLI in Combination with DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma (PR Newswire)
Mar-01-26 04:27AM	Is Halozyme Therapeutics (HALO) a Buy Post Earnings? (Insider Monkey)
11:54AM	Loading…
Feb-28-26 11:54AM	Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory (Insider Monkey)
Feb-25-26 08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-24-26 11:05PM	2 Reasons to Like HALO (and 1 Not So Much) (StockStory)
Feb-19-26 09:25AM	Halozyme (HALO) Loses 9% on Weak Earnings (Insider Monkey)
Feb-18-26 01:06PM	Tech Stocks Rebound, Crude Rallies Above $64 On Iran Tensions: What's Moving Markets Wednesday? (Benzinga) -9.01%
11:17AM	Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues (Zacks)
08:30AM	Halozyme Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
12:01AM	Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-17-26 07:43PM	Halozyme Therapeutics Q4 Earnings Call Highlights (MarketBeat)
06:30PM	Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings (Zacks)
05:10PM	Loading…
05:10PM	Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales (StockStory)
04:19PM	Halozyme Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE (PR Newswire)
Feb-16-26 09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
08:30AM	Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today (Zacks)
Feb-15-26 08:00AM	The biopharma company trying to simplify drug delivery for patients (Yahoo Finance Video)
Feb-13-26 09:15AM	Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics (Zacks)
Feb-11-26 10:00AM	Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline (Zacks)
Feb-10-26 04:05PM	Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results (PR Newswire)
11:15AM	Biotech: Halozyme CEO explains what it looks for in M&A targets (Yahoo Finance Video)
10:00AM	Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-05-26 09:57AM	This Medical Technology Leader Sees Growth Into The 2040s (Investor's Business Daily)
Feb-04-26 06:09PM	Silicon Motion Moves Higher On Rosy Outlook (Investor's Business Daily)
10:39AM	Google Stock: What The Buy Side Expects From Cloud Computing Business (Investor's Business Daily)
09:40AM	Loading…
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
08:21AM	Stock Market Today: Dow Rises Ahead Of Jobs Data; AMD Plunges On Earnings (Live Coverage) (Investor's Business Daily)
Feb-03-26 04:57PM	Stock Market Today: Nasdaq Gets Hit Hardest As Techs Sink; Palantir Climbs After Earnings (Live Coverage) (Investor's Business Daily)
08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Feb-02-26 05:33PM	IBD Stock Of The Day Halozyme Eyes Two Buy Points; How It's 'Layering' Up For Future Growth (Investor's Business Daily)
12:10PM	Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-31-26 08:00AM	5 Stocks To Watch Trade Near Buy Points; Three Are Data Center Plays (Investor's Business Daily)
Jan-30-26 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
08:30AM	If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
Jan-29-26 01:25PM	H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating (Insider Monkey)
11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
Jan-28-26 01:58PM	Halozyme Therapeutics Projects Sustained Growth Well Into 2040 (Benzinga)
12:02PM	Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s (MarketBeat)
06:30AM	Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance (PR Newswire)
06:20AM	Halozyme buys a biotech startup; Cytokinetics launches heart drug (BioPharma Dive)
Jan-24-26 02:20PM	2 Under-the-Radar Biotech Stocks Set to Boom in 2026 (Motley Fool)
Jan-22-26 09:52PM	TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance (Insider Monkey)
Jan-20-26 04:05PM	Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update (PR Newswire)
02:38PM	Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade (Insider Monkey)
Jan-19-26 07:20PM	Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty (Motley Fool)
Jan-18-26 10:36PM	Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks (StockStory)
Jan-15-26 01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
Jan-13-26 09:50AM	Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Jan-12-26 09:40AM	Are Medical Stocks Lagging Ardelyx (ARDX) This Year? (Zacks)
Jan-09-26 11:40AM	HALO or AXSM: Which Is the Better Value Stock Right Now? (Zacks)
Jan-08-26 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:00AM	Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE (PR Newswire)
Jan-07-26 11:04PM	Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
11:25AM	Smorgasbord Of Buy Points Kicks Off 2026. Google, Nvidia On The Menu. (Investor's Business Daily)
Jan-06-26 09:38AM	CoreWeave initiated, Shopify downgraded: Wall Street's top analyst calls (The Fly)
Jan-05-26 07:00AM	Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity (PR Newswire)
Jan-01-26 03:30PM	Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 (StockStory)
Dec-31-25 11:41AM	Here's What Analysts Think About Halozyme Therapeutics (HALO) (Insider Monkey)
Dec-23-25 12:46PM	Halozyme Therapeutics Stock Sees Relative Strength Rating (Investor's Business Daily)
03:53AM	J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised) (Zacks)
Dec-19-25 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Dec-18-25 12:48PM	J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Zacks)
07:00AM	U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer (PR Newswire)
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire)
Dec-09-25 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Dec-08-25 04:05PM	Jim Lang Elected to Halozyme's Board of Directors (PR Newswire)
Dec-06-25 09:50AM	The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. (Motley Fool)
Dec-05-25 09:56AM	Toast upgraded, PayPal downgraded: Wall Streets top analyst calls (TipRanks)
Dec-04-25 02:22PM	Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case (The Wall Street Journal)
01:26PM	Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany (PR Newswire)
09:53AM	Toast upgraded, PayPal downgraded: Wall Street's top analyst calls (The Fly)
Dec-03-25 12:02PM	AppLovin Stock Rides Swarm Of Setups Beyond Just Mining, Medical Names (Investor's Business Daily)
11:30AM	Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? (Zacks)
Dec-01-25 12:00PM	What Makes Halozyme Therapeutics (HALO) a New Buy Stock (Zacks)
08:30AM	If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
08:04AM	Meridian Growth Fund Trimmed Halozyme Therapeutics, Inc. (HALO) Following Appreciation (Insider Monkey)
Nov-27-25 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
09:07AM	This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside - Here's Why (Insider Monkey)
Nov-25-25 08:30AM	Halozyme to Participate in the 8th Annual Evercore Healthcare Conference (PR Newswire)
Nov-21-25 08:05AM	This Medical Technology Leader Sees Profit Growth Topping 44% (Investor's Business Daily)
Nov-18-25 08:50AM	Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery (PR Newswire)
Nov-17-25 01:17PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
08:45AM	Why I Keep Buying These 10 Incredible Growth Stocks (Motley Fool)
07:00AM	Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab (PR Newswire)
Nov-12-25 02:43PM	Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? (Investor's Business Daily)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-11-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-07-25 01:20PM	Halozyme Therapeutics Stock Sees Improved RS Rating (Investor's Business Daily)
08:30AM	FDA Approved DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma (PR Newswire)
Nov-06-25 11:37PM	Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 (PR Newswire)
Nov-05-25 04:05PM	Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 (PR Newswire)
Nov-04-25 10:31AM	Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View (Zacks)
12:01AM	Halozyme Therapeutics Inc (HALO) Q3 2025 Earnings Call Highlights: Record Royalty Revenue and ... (GuruFocus.com)
Nov-03-25 06:30PM	Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates (Zacks)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Torley Helen	PRESIDENT AND CEO	Apr 06 '26	Option Exercise	12.07	10,000	120,700	777,780	Apr 07 05:13 PM
Torley Helen	PRESIDENT AND CEO	Apr 06 '26	Sale	63.50	10,000	634,982	767,780	Apr 07 05:13 PM
Torley Helen	PRESIDENT AND CEO	Apr 01 '26	Option Exercise	12.07	20,000	241,400	787,780	Apr 02 06:28 PM
Torley Helen	PRESIDENT AND CEO	Apr 02 '26	Option Exercise	12.07	20,000	241,400	787,780	Apr 02 06:28 PM
Torley Helen	PRESIDENT AND CEO	Apr 01 '26	Sale	65.38	20,000	1,307,516	767,780	Apr 02 06:28 PM
Torley Helen	PRESIDENT AND CEO	Apr 02 '26	Sale	64.24	20,000	1,284,721	767,780	Apr 02 06:28 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Mar 09 '26	Option Exercise	33.51	20,000	670,200	34,366	Mar 10 07:18 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Mar 10 '26	Option Exercise	33.51	1,546	51,806	15,912	Mar 10 07:18 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Mar 09 '26	Sale	67.80	20,000	1,356,072	14,366	Mar 10 07:18 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Mar 10 '26	Sale	67.64	8,857	599,087	7,055	Mar 10 07:18 PM
CORTNEY A CAUDILL	Officer	Mar 10 '26	Proposed Sale	67.64	8,857	599,088		Mar 10 04:05 PM
CORTNEY A CAUDILL	Officer	Mar 09 '26	Proposed Sale	67.80	20,000	1,356,062		Mar 09 04:18 PM
Torley Helen	PRESIDENT AND CEO	Mar 02 '26	Option Exercise	12.07	20,000	241,400	787,780	Mar 04 06:56 PM
Torley Helen	PRESIDENT AND CEO	Mar 03 '26	Option Exercise	12.07	20,000	241,400	787,780	Mar 04 06:56 PM
Torley Helen	PRESIDENT AND CEO	Mar 04 '26	Option Exercise	12.07	10,000	120,700	777,780	Mar 04 06:56 PM
Torley Helen	PRESIDENT AND CEO	Mar 02 '26	Sale	69.69	20,000	1,393,894	767,780	Mar 04 06:56 PM
Torley Helen	PRESIDENT AND CEO	Mar 03 '26	Sale	69.01	20,000	1,380,149	767,780	Mar 04 06:56 PM
Torley Helen	PRESIDENT AND CEO	Mar 04 '26	Sale	70.21	10,000	702,114	767,780	Mar 04 06:56 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Feb 20 '26	Option Exercise	0.00	2,666	0	15,403	Feb 24 06:19 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 23 '26	Option Exercise	0.00	7,011	0	51,392	Feb 24 06:16 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 20 '26	Option Exercise	0.00	5,332	0	47,257	Feb 24 06:16 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 23 '26	Option Exercise	0.00	6,688	0	42,102	Feb 24 06:14 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 20 '26	Option Exercise	0.00	5,332	0	38,290	Feb 24 06:14 PM
Torley Helen	PRESIDENT AND CEO	Feb 23 '26	Option Exercise	0.00	22,436	0	779,884	Feb 24 06:12 PM
Torley Helen	PRESIDENT AND CEO	Feb 20 '26	Option Exercise	0.00	16,757	0	766,488	Feb 24 06:12 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 16 '26	Option Exercise	0.00	16,812	0	48,406	Feb 17 06:53 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '26	Option Exercise	0.00	23,773	0	40,231	Feb 17 06:52 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '26	Option Exercise	0.00	89,055	0	777,336	Feb 17 06:51 PM
Torley Helen	PRESIDENT AND CEO	Feb 03 '26	Option Exercise	12.07	20,000	241,400	728,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 04 '26	Option Exercise	12.07	20,000	241,400	728,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 05 '26	Option Exercise	12.07	10,000	120,700	718,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 04 '26	Sale	77.24	20,000	1,544,820	708,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 03 '26	Sale	76.12	20,000	1,522,317	708,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 05 '26	Sale	78.64	10,000	786,366	708,719	Feb 05 07:38 PM
Helen Torley	President, CEO, Director	Feb 03 '26	Proposed Sale	74.45	150,000	11,167,500		Feb 03 04:17 PM
Connaughton Bernadette	Director	Jan 05 '26	Sale	70.25	2,000	140,500	40,123	Jan 06 06:55 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jan 03 '26	Option Exercise	0.00	7,611	0	38,424	Jan 06 06:55 PM
BERNADETTE CONNAUGHTON	Director	Jan 05 '26	Proposed Sale	70.31	2,000	140,620		Jan 05 04:39 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Nov 01 '25	Option Exercise	0.00	9,326	0	17,000	Dec 19 05:39 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Nov 01 '25	Sale	65.19	4,263	277,905	12,737	Dec 19 05:39 PM
Connaughton Bernadette	Director	Dec 01 '25	Sale	71.60	829	59,356	42,123	Dec 01 07:50 PM
Torley Helen	PRESIDENT AND CEO	Dec 01 '25	Option Exercise	8.11	16,569	134,375	725,288	Dec 01 07:31 PM
Torley Helen	PRESIDENT AND CEO	Dec 01 '25	Sale	68.92	16,569	1,141,925	708,719	Dec 01 07:31 PM
Torley Helen	PRESIDENT AND CEO	Nov 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 12 '25	Sale	70.55	20,000	1,410,990	733,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 11 '25	Sale	69.13	20,000	1,382,600	733,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 10 '25	Sale	68.72	20,000	1,374,339	733,719	Nov 12 06:54 PM
Connaughton Bernadette	Director	Nov 10 '25	Sale	68.48	2,000	136,960	42,952	Nov 12 05:58 PM
Torley Helen	PRESIDENT AND CEO	Oct 01 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 03 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 02 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 01 '25	Sale	75.35	20,000	1,507,024	733,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 02 '25	Sale	71.20	20,000	1,424,083	733,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 03 '25	Sale	69.03	20,000	1,380,638	733,719	Oct 03 06:00 PM
Connaughton Bernadette	Director	Oct 01 '25	Sale	75.24	2,000	150,481	44,952	Oct 01 06:29 PM
Helen Torley	President, CEO, Director	Oct 01 '25	Proposed Sale	73.34	136,569	10,015,970		Oct 01 04:26 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 22 '25	Sale	77.95	2,227	173,584	22,079	Sep 23 04:15 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Option Exercise	12.11	12,406	150,217	44,306	Sep 11 05:09 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Sale	75.71	20,000	1,514,267	24,306	Sep 11 05:09 PM
NICOLE LABROSSE	Officer	Sep 10 '25	Proposed Sale	76.07	22,227	1,690,808		Sep 10 04:37 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Sale	74.44	20,000	1,488,726	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Sale	74.04	20,000	1,480,772	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Sale	73.76	20,000	1,475,128	733,719	Sep 04 05:41 PM
Connaughton Bernadette	Director	Sep 02 '25	Sale	73.68	4,000	294,736	46,952	Sep 02 08:11 PM
BERNADETTE CONNAUGHTON	Director	Sep 02 '25	Proposed Sale	73.15	8,829	645,841		Sep 02 04:38 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Sale	64.32	20,000	1,286,351	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Sale	63.51	20,000	1,270,121	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Sale	63.05	20,000	1,260,917	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Sale	57.43	20,000	1,148,618	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Sale	56.43	20,000	1,128,655	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Sale	55.51	20,000	1,110,245	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Sale	53.73	20,000	1,074,620	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Sale	52.96	20,000	1,059,200	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Sale	52.57	20,000	1,051,460	733,719	Jun 24 05:40 PM
Helen Torley	President, CEO, Director	Jun 20 '25	Proposed Sale	53.15	240,000	12,756,000		Jun 20 04:25 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jun 12 '25	Option Exercise	0.00	5,035	0	33,524	Jun 13 05:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HALO

Halozyme Therapeutics Inc

Upgrade your Finviz experience